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Shiga toxin (Stx) is the principal virulence factor during Shiga toxin-producing Escherichia
coli (STEC) infections. We have previously reported the inactivation of bacteriophage
encoding Stx after treatment with chitosan, a linear polysaccharide polymer with
cationic properties. Cationic antimicrobial peptides (cAMPs) are short linear aminoacidic
sequences, with a positive net charge, which display bactericidal or bacteriostatic
activity against a wide range of bacterial species. They are promising novel antibiotics
since they have shown bactericidal effects against multiresistant bacteria. To evaluate
whether cationic properties are responsible for bacteriophage inactivation, we tested
seven cationic peptides with proven antimicrobial activity as anti-bacteriophage agents,
and one random sequence cationic peptide with no antimicrobial activity as a control.
We observed bacteriophage inactivation after incubation with five cAMPs, but no
inactivating activity was observed with the random sequence cationic peptide or with the
non-alpha helical cAMP Omiganan. Finally, to confirm peptide-bacteriophage interaction,
zeta potential was analyzed by following changes on bacteriophage surface charges
after peptide incubation. According to our results we could propose that: (1) direct
interaction of peptides with phage is a necessary step for bacteriophage inactivation, (2)
cationic properties are necessary but not sufficient for bacteriophage inactivation, and
(3) inactivation by cationic peptides could be sequence (or structure) specific. Overall
our data suggest that these peptides could be considered a new family of molecules
potentially useful to decrease bacteriophage replication and Stx expression.
Keywords: bacteriophages (phages), antimicrobial peptides, Escherichia coli O157, hemolytic uremic syndrome
(HUS), anti-infective agents
INTRODUCTION
Infections with Shiga toxin-producing Escherichia coli (STEC) strains are a serious public health
problem. Children infected with STEC strains present diarrhea, hemorrhagic colitis, and a
percentage of patients can develop Hemolytic Uremic Syndrome (HUS).
Shiga toxin (Stx) is the main virulence factor during STEC infections. Because the gene encoding
for Stx is inside the prophage genome, these strains are also known as Escherichia coli Shiga
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Toxin-Encoding Bacteriophages. During STEC infection, the
bacteriophage is cleaved and the replication and Stx expression
take place inside the gut. Then, free bacteriophages are able to
infect other susceptible bacteria present in the gut, exacerbating
Stx expression (Cornick et al., 2006). Currently, there are no
effective treatments or vaccines available, and for this reason
bacteriophage inactivation treatments are a promising strategy to
prevent Stx expression after STEC infections.
Previously, we showed that chitosan has anti-bacteriophage
activity in vitro and in vivo (Amorim et al., 2014). Chitosan
is a cationic linear polysaccharide polymer obtained after the
deacetylation of chitin; this polymer has been widely-used as an
antimicrobial agent against several microorganisms (Kong et al.,
2010). In a previous work Maffía and collaborators designed a
group of new cationic antimicrobial peptides and tested them
against a broad panel of multi-resistant clinical bacterial isolates
(Faccone et al., 2014). In order to evaluate whether these
sequences could affect bacteriophage infection we tested seven
previously designed cAMPs (Faccone et al., 2014; Hollmann
et al., 2016; Maturana et al., 2017) as potential anti-bacteriophage
agents. To analyze the effect of these peptides, we used
them to inactivate a previously reported mutant bacteriophage
(φ1TOX:GFP) in which the stx operon has been replaced by a
gene encoding for the green fluorescent protein (GFP) (Amorim
et al., 2014). Five of these peptides were previously analyzed
and displayed antimicrobial activity in different bacterial strains
and structure as alpha helix in contact with lipid membranes
(P5, P8, P8.1, P2, and P6.2). The other two peptides tested were
Omiganan, a linear Beta-sheet cAMP derived from indolicidin
that underwent clinical trials with activity against S. aureus;
and a random sequence peptide with cationic charge but no
antimicrobial activity (Faccone et al., 2014; Hollmann et al., 2016)
Therefore, the objective of this work was to evaluate if
this group of cAMPs could inactivate Shiga toxin- encoding
bacteriophages.
MATERIALS AND METHODS
Cationic Peptides
Each peptide was synthesized with C terminus amidation.
Peptides were synthesized and obtained at a purity grade of
>95% by HPLC (GenScript Co., Piscataway, NJ 08854, USA).
Cationic alpha helical peptides P5, P8, P8.1, P2, and P6.2 were
previously designed using a combined rational and computer
assisted approach, identifying short putative active regions from
AMP databases (Faccone et al., 2014; Maturana et al., 2017).
Peptide sequences are: peptide 2: GLLKKWLKKWKEFKRIVG
Y; peptide 8.1: RIVQRIAKWAKKWYKAGK, peptide 6.2: GLL
RKWGKKWKEFLRRVWK; peptide 5: RIVQRIKKWLLKWKK
LGY; peptide 8: RIVQRILKWLKKWYKLGK. Omiganan (MBI-
226): ILRWPWWPWRRK; Random non-alpha helical peptide:
MVVFSVPKFKSTVAKLLSSA.
Bacteriophage Induction
E. coli C6001TOX:GFP strain was obtained from Dr. Weiss,
University of Cincinnati (Gamage et al., 2003). E. coli
C6001TOX:GFP is a lysogenized C600 strain carrying the
933W bacteriophage in which the stx gene was replaced by
the gfp sequence. Since this strain does not produce Shiga
toxin, it represents a safety option to evaluate bacteriophage
infection. E. coli C6001TOX:GFP strain was grown in Luria
Broth (LB) plus 10mM CaCl2 and chloramphenicol (Sigma)
(15µg/ml final concentration) overnight (ON) at 37◦C under
agitation. The ON culture was diluted to OD 600 nm = 0.1 in
LB plus 10mM CaCl2 and chloramphenicol (Sigma) (15µg/ml
final concentration). Induction was carried out by adding
ciprofloxacin to a final concentration of 40 ng/ml (Ciprax 200,
Roemmers). Bacteria were incubated for 6 h at 37◦C under
agitation and cultures were then centrifuged at 5,000 rpm for
15min. The bacteriophage-containing supernatant was purified
by sucrose ultracentrifugation. Briefly, supernatant containing
bacteriophage was ultracentrifugated at 35.000 × g (Beckman
XL-70, Rotor J-20), at 4◦C during 2 h with 35% sucrose solution.
The pellet was resuspended in 1ml of PBS, filtered with 0.2µm
filters (MC-PES-02S, Microclar) and kept at 4◦C until the
titration assay was performed.
Titration Assay
E. coli strain (ATCC 37197) was grown in LB plus ampicillin (0.05
mg/ml final concentration) overnight at 37◦C under agitation at
200 rpm. The culture was diluted 1:100 in LB plus ampicillin
(0.05 mg/ml final concentration) and incubated for 2 additional
hours at 37◦C under agitation. At the end of the incubation,
1,000 µl samples of the E. coli strain were incubated with 100
µl of a suspension containing bacteriophages for 30min at room
temperature. At the end of this incubation, 3ml of Top Agar
(Tryptone 1%; NaCl 0.5%; Agar 0.7%) plus CaCl2 (10mM final
concentration) was added, and plated on LB-Amp agar plates.
Plates were incubated at 37◦C and lysis plaques were counted
after 24 h.
Anti-Bacteriophage Activity
Bacteriophage 1TOX:GFP (φ1TOX:GFP) was incubated with
peptides diluted in 400 µl of PBS at a final concentration of
0.1µg/ml, 5µg/ml, 10µg/ml, or 50µg /ml for 16 h at 37◦C. After
incubation, bacteriophage titers were measured as described
above. E. coli strain (ATCC 37197), used for titration assay, was
incubated with peptides alone as a control. During titration assay,
the final concentration of peptides in the bacterial suspension was
1.4, 2.8, and 14µg/ml, respectively.
Z Potential
The Zeta potential measured in volts (ξ) was calculated using
the Smoluchowski equation: where η is the viscosity of the
suspension at 20◦C, D is the dielectric constant of the solution
at 20◦C and µ is the electrophoretic mobility of particles
(micrometer/s per volt/cm). Bacteriophage was incubated with
a solution containing peptide 5 or Omiganan at 5.7µg/ml
final concentration for 30min at 25◦C under gentle agitation.
Measurements were conducted in a Nano Particle Analyzer
SZ100 (Horiba) at 25◦C, each value represents the average of two
independents batches, and 100 individual determinations were
obtained per batch.
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Dynamic Light Scattering
Dynamic light scattering experiments were carried out on an
Analyzer SZ100 (Horiba) with a backscattering detection at
173◦, using disposable polystyrene cells. The bacteriophage
suspensions (with or without peptide) were left equilibrating for
15min at 25◦C. Normalized intensity autocorrelation functions
were analyzed using the CONTIN method (Provencher, 1982),
yielding a distribution of diffusion coefficients (D). D is used
to calculate the hydrodynamic diameter (DH) through the
Stokes-Einstein relationship: (3) where k is the Boltzmann
constant, T the absolute temperature, and η the viscosity of
the medium. The DH value was calculated from a set of 15
measurements (∼13 runs each) for the bacteriophage in presence
of peptide p5 or alone. The DH of the sample was obtained from
the peak with the highest scattered light intensity (i.e., the mode)
in light scattering intensity distributions.
Statistical Analysis
The significance of the difference between concentrations was
analyzed using Prism 5.0 software (GraphPad Software), and
the P-value is indicated by asterisks in the figures. Data
correspond to mean ± standard errors of the mean (SEM) for
each concentration using triplicates. Statistical differences were
determined using the one-way analysis of variance (ANOVA).
Comparisons a posteriori between groups were performed using
Tukey’s Multiple Comparison Test analysis.
RESULTS
Anti-Bacteriophage Activity
Bacteriophages were incubated with 0.1, 5, 10, or 50µg/ml
of each peptide. After incubation, inactivation was evaluated
analyzing the bacteriophage capacity to infect E. coli. The
seven peptides displayed different inactivation activities against
the bacteriophage. Peptides 6.2, 5, and 8 showed the highest
inactivation activity, inactivating nearly the 100% of phages in the
conditions tested (Figures 1B, 2A,B).
On the other hand, Peptides 2 and 8.1 showed the lowest
inactivation activity among the cAMP tested (Figures 1A, 2C).
Random peptide and Omiganan showed no inactivation
activity against bacteriophage under the conditions tested
(Figure 3).
It is important to notice that, according to the protocol we
used, after the incubation of each peptide with phages, the
peptide-phage mixture is plated on the E. coli lawn. For that
reason a possible antimicrobial activity of these cAMPS on this
E. coli strain had to be previously assessed, and no visible activity
of the peptides per se was observed. It is worth mentioning
that the final peptide concentration affecting the bacterial lawn
during the titration assay ranged from1.4 to 14µg/ml, which is a
much lower concentration than the effective minimal inhibitory
activity (MIC) previously obtained for each peptide on E. coli.
In addition we performed a MIC assay for these peptides at
different concentrations between 54 and 3.3µg/ml on the E. coli
C6001TOX:GFP strain, and we found no antimicrobial activity
below 27µg/ml for all the peptides tested.
Bacteriophage-Peptide Interaction
The interaction between peptides and bacteriophages was
analyzed using Zeta potential assays. We observed that peptide
5 was able to modify the surface charge of the bacteriophages,
by decreasing the net negatively charge exposed by the
bacteriophage. The results strongly suggest that positively
charged peptides and bacteriophages are interacting through
electrostatic charges (Figure 4). Interestingly, the same behavior
was found with peptide Omiganan, although this peptide did not
show anti-bacteriophage activity.
We used DLS to assess whether the size of the bacteriophage
was altered as a consequence of its interaction with the peptides,
or inducing any aggregation effect. The results suggest that
peptides do not affect the hydrodynamic diameter of the
bacteriophage (Figure 5).
DISCUSSION
It is well known that bacteriophage induction is required for
HUS development (Tyler et al., 2013). Additionally, it was also
reported that bacteriophage was able to infect bacteria in vivo and
in vitro (Schmidt, 2001; Cornick et al., 2006).
We have previously observed a dramatical decrease of GFP
expression in vivo in mice treated with chitosan after infection
with a non-pathogenic E. coli strain containing a mutant
bacteriophage in which the gene of stx was replaced by gfp
sequence (Amorim et al., 2014).
In order to evaluate another anti-bacteriophage agent, we
analyzed a group of cationic peptides. In this work, and for
the first time ever reported, we observed that seven cAMPs
were able to inactivate bacteriophage infection on bacteria. It
is worth mentioning that in previous works we observed that
all the peptides, except random peptide, displayed antimicrobial
activity (Faccone et al., 2014; Hollmann et al., 2016; Maturana
et al., 2017). Interestingly, even though they are both cationic
sequences, Omiganan and random peptide did not display any
bacteriophage inactivation activity. In regard to the structure,
unlike the rest of the sequences tested, these two peptides did
not structure as alpha helix in contact with lipidic membranes
(Faccone et al., 2014).
It is interesting to note that for peptides 2 and 6.2 we observed
a bell curve shaped behavior of the phage neutralizing activity
vs. concentration curve. This kind of behavior is more or less
common among some drugs, and in this case we could speculate
that the tendency to aggregate that these particular peptides have
at high doses, due to the high number of hydrophobic amino
acids they harbor, could be responsible, at least in part, for
this phenomenon. This tendency to aggregate, which depends
on the amino acid composition and the structure the peptide
sequence displays, is probably responsible for the inactivation of
the peptide as we increase the concentration andmore aggregates
are formed.
In order to evaluate if a direct interaction between peptides
and bacteriophage is involved in the inactivation activity,
zeta potential experiments were conducted, using peptide 5
as a model. The result obtained (Figure 4) confirmed an
electrostatic interaction between peptide and bacteriophage.
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FIGURE 1 | Bacteriophage inactivation by cationic peptides. (A) Peptide P.2. (B) Peptide 6.2. After pre-incubation of bacteriophages with different concentrations of
peptides the inactivation was measured by titration of E. coli, strain (ATCC 37197). Prism 5.0 software (GraphPad Software) was used to determine statistical
significance between different samples. Peptide 2: *p < 0.05, ***p < 0.0001. Peptide 6.2: **p < 0.05, ***p < 0.0001.
FIGURE 2 | Bacteriophage inactivation by cationic peptides. (A) Peptide 5 (B) Peptide 8 (C) Peptide 8.1. After pre-incubation of bacteriophages with different
concentrations of peptides the inactivation was measured by titration of E. coli, strain (ATCC 37197). Prism 5.0 software (GraphPad Software) was used to determine
statistical significance between different samples using one-way analysis of variance (ANOVA). Peptide 5: *p = 0.0313. Peptide 8: **p < 0.005, ***p < 0.0001. Peptide
8.1: *p < 0.05, **p = 0.008.
FIGURE 3 | Bacteriophage inactivation by control peptides. (A) Omiganan, a commercial cationic beta sheet peptide (B) Random sequence, a cationic non alpha
helical peptide. Prism 5.0 software (GraphPad Software) was used to determine statistical significance between different samples using one-way analysis of variance
(ANOVA). Omiganan: ns. Random: ns.
However, Omiganan, that displayed no inactivation activity,
also showed direct interaction with the bacteriophage. These
findings allow us to hypothesize that cationic properties, that are
probably responsible for the interaction between peptides and
bacteriophage, are necessary but not sufficient for achieving an
inactivation activity.
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FIGURE 4 | Zeta potential measurements of bacteriophage incubated with
peptides P5 or Omiganan (OMI), or in buffer solution (control). Each point
represents the mean of 2 independent batches ± SEM. **P < 0.01;
***P < 0.001, one-way ANNOVA followed by a Dunnett post-test for multiple
comparisons vs. the control.
FIGURE 5 | Average hydrodynamic diameter of bacteriophage incubated with
peptides 5 or in buffer solution (control). Ns, Not significant, t-test (unpaired).
Overall, our results lead us to hypothesize that specific
interaction between cAMPs and bacteriophage proteins, after a
first approach driven by electrostatic force, might be responsible
for infection inhibition. We hypothesize that the complex
generated after bacteriophage-peptide incubation could be
responsible for preventing the bacteriophage adhesion on the
bacterial cell wall (Figure 6). Further experiments analyzing
bacteriophage proteins implicated on bacterial adhesion should
be performed.
In the race to find a therapy to decrease the risk of HUS
development, bacteriophage inactivation by cAMPs could be a
promising new strategy for the inhibition of the bacteriophage
replication and Stx expression. These peptides could be
considered a new family of molecules potentially useful for a
future HUS treatment.
The results obtained in this work, using novel designed
cAMPS, open another relevant area of study related with
the interactions between natural immune cAMPs and
bacteriophages, for instance cAMPS produced by human
leukocytes at the site of infection. If these results could be
replicated with human cAMPs, a whole new perspective of SUH
development could arise, in which human cationic peptides could
FIGURE 6 | Schematic representation of bacteriophage-peptide interaction
and its role in bacterial infection.
play a crucial role in the natural control of phage replication.
Altogether, these results highlight that cationic peptides are
potential candidates for future research in alternative treatments
for STEC infections.
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